Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 8213 results

  1. Artificial Intelligence in MRI for prostate cancer diagnosis

    Awaiting development Reference number: GID-HTE10089 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  2. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development Reference number: GID-TA10904 Expected publication date:  03 December 2025

    Technology appraisal guidance
    In development

  4. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235

    In development Reference number: GID-TA11246 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  6. ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)

    In development Reference number: GID-TA11850 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  7. Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]

    In development Reference number: GID-TA11201 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  8. Teprotumumab for treating thyroid eye disease [ID6432]

    In development Reference number: GID-TA11531 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  10. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  11. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  12. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  13. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  14. Insulin efsitora alfa for treating type 2 diabetes ID6499

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  15. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation